-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Bioventus (NYSE:BVS) Releases FY 2022 Earnings Guidance
Bioventus (NYSE:BVS) Releases FY 2022 Earnings Guidance
Bioventus (NYSE:BVS – Get Rating) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $0.47-$0.57 for the period, compared to the consensus estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Wall Street Analyst Weigh In
Separately, Morgan Stanley upped their price target on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
Get Bioventus alerts:Bioventus Price Performance
NYSE:BVS traded down $0.24 during trading hours on Friday, reaching $8.23. 141,473 shares of the company traded hands, compared to its average volume of 116,706. The firm's 50-day moving average is $8.15 and its 200-day moving average is $10.51. The stock has a market cap of $637.41 million, a P/E ratio of 12.66 and a beta of 2.07. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.39 and a quick ratio of 1.05. Bioventus has a 1-year low of $6.30 and a 1-year high of $17.53.
Bioventus (NYSE:BVS – Get Rating) last announced its earnings results on Thursday, August 11th. The company reported $0.10 EPS for the quarter, missing analysts' consensus estimates of $0.14 by ($0.04). The company had revenue of $140.33 million for the quarter, compared to analyst estimates of $140.01 million. Bioventus had a negative net margin of 4.26% and a positive return on equity of 10.35%. During the same quarter last year, the company posted $0.16 EPS. Equities research analysts expect that Bioventus will post 0.54 earnings per share for the current fiscal year.Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its stake in shares of Bioventus by 1,845.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company's stock worth $30,000 after purchasing an additional 2,030 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Bioventus by 123.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,132 shares of the company's stock worth $44,000 after purchasing an additional 1,733 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bioventus by 255.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,593 shares of the company's stock worth $52,000 after purchasing an additional 5,454 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Bioventus during the 2nd quarter worth $75,000. Finally, Walleye Capital LLC purchased a new position in shares of Bioventus during the 2nd quarter worth $77,000. Hedge funds and other institutional investors own 86.85% of the company's stock.
Bioventus Company Profile
(Get Rating)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
See Also
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
Bioventus (NYSE:BVS – Get Rating) updated its FY 2022 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of $0.47-$0.57 for the period, compared to the consensus estimate of $0.65. The company issued revenue guidance of $547.50 million-$562.50 million, compared to the consensus revenue estimate of $552.13 million.
Bioventus(NYSE:BVS-GET Rating)週五更新了2022財年收益指引。該公司提供了該季度每股收益(EPS)0.47-0.57美元的指引,而普遍預期為0.65美元。該公司發佈的收入指引為5.475億至5.625億美元,而普遍的收入預期為5.5213億美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
Separately, Morgan Stanley upped their price target on Bioventus from $11.00 to $12.00 and gave the stock an overweight rating in a report on Friday, August 12th.
另外,摩根士丹利在8月12日星期五的一份報告中將Bioventus的目標價從11.00美元上調至12.00美元,並給予該股增持評級。
Bioventus Price Performance
Bioventus性價比
NYSE:BVS traded down $0.24 during trading hours on Friday, reaching $8.23. 141,473 shares of the company traded hands, compared to its average volume of 116,706. The firm's 50-day moving average is $8.15 and its 200-day moving average is $10.51. The stock has a market cap of $637.41 million, a P/E ratio of 12.66 and a beta of 2.07. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.39 and a quick ratio of 1.05. Bioventus has a 1-year low of $6.30 and a 1-year high of $17.53.
紐約證交所:BVS週五交易時段下跌0.24美元,至8.23美元。該公司有141,473股易手,而其平均成交量為116,706股。該公司的50日移動均線切入位在8.15美元,200日移動均線切入位在10.51美元。該股市值為6.3741億美元,市盈率為12.66,貝塔係數為2.07。該公司的債務權益比為0.68,流動比率為1.39,速動比率為1.05。Bioventus的一年低點為6.30美元,一年高位為17.53美元。
Institutional Inflows and Outflows
機構資金流入和流出
Large investors have recently made changes to their positions in the business. PNC Financial Services Group Inc. lifted its stake in shares of Bioventus by 1,845.5% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,140 shares of the company's stock worth $30,000 after purchasing an additional 2,030 shares during the period. Lazard Asset Management LLC lifted its stake in shares of Bioventus by 123.9% during the 1st quarter. Lazard Asset Management LLC now owns 3,132 shares of the company's stock worth $44,000 after purchasing an additional 1,733 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bioventus by 255.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,593 shares of the company's stock worth $52,000 after purchasing an additional 5,454 shares during the period. Principal Financial Group Inc. purchased a new position in shares of Bioventus during the 2nd quarter worth $75,000. Finally, Walleye Capital LLC purchased a new position in shares of Bioventus during the 2nd quarter worth $77,000. Hedge funds and other institutional investors own 86.85% of the company's stock.
大型投資者最近改變了他們在該業務中的頭寸。PNC金融服務集團在第一季度增持了1,845.5%的Bioventus股票。PNC金融服務集團(PNC Financial Services Group Inc.)在此期間額外購買了2,030股,目前持有該公司2,140股股票,價值30,000美元。Lazard Asset Management LLC在第一季度增持了123.9%的Bioventus股票。Lazard Asset Management LLC在此期間額外購買了1,733股,現在擁有3,132股該公司股票,價值44,000美元。蘇黎世廣東銀行在第二季度增持了255.0%的Bioventus股份。Zurcher Kantonalbank蘇黎世廣東銀行在此期間又購買了5454股,現在擁有7593股該公司股票,價值52,000美元。信安金融集團公司在第二季度購買了價值7.5萬美元的Bioventus新股。最後,Walleye Capital LLC在第二季度購買了價值77,000美元的Bioventus新股票頭寸。對衝基金和其他機構投資者持有該公司86.85%的股票。
Bioventus Company Profile
Bioventus公司簡介
(Get Rating)
(獲取評級)
Bioventus Inc a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products.
Bioventus公司是一家醫療設備公司,專注於開發臨牀治療方法並將其商業化,這些治療方法在美國和國際上參與並增強了人體的自然癒合過程。該公司的產品組合包括疼痛治療,其中包括非手術關節疼痛注射療法,以及周圍神經刺激產品。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Bioventus (BVS)
- 2 EV Suppliers Powering To Gains After Raising Views
- Applied Materials Results Show A Slowing Semiconductor Market
- MarketBeat: Week in Review 8/15 – 8/19
- Near-Term Headwinds Present An Opportunity In Ross Stores
- Apple's Stock Could Be On The Verge Of Another 30% Rally
- 免費獲取StockNews.com關於Bioventus(BVS)的研究報告
- 2家電動汽車供應商在提出意見後上漲
- 應用材料公司業績顯示半導體市場放緩
- MarketBeat:回顧中的一週8/15-8/19
- 近期逆風為Ross Stores帶來機遇
- 蘋果股價可能再次上漲30%
Receive News & Ratings for Bioventus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioventus and related companies with MarketBeat.com's FREE daily email newsletter.
收到《Bioventus Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Bioventus和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧